Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.53 |
| ▸ | KDR | P35968 | 16/20 | 0.53 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427451 | 0.96 | EGFR (0.52) | EGFRKDRAURKABRAF | |
| SCHEMBL5494771 | 0.95 | EGFR (0.53) | EGFRKDRAURKABRAF | |
| SCHEMBL6774801 | 0.90 | EGFR (0.51) | EGFRKDRAURKABRAF | |
| SCHEMBL5500589 | 0.90 | AURKA (0.54) | EGFRKDRAURKABRAF | |
| SCHEMBL4422030 | 0.88 | EGFR (0.57) | EGFRKDRAURKABRAF | |
| SCHEMBL4417552 | 0.84 | EGFR (0.59) | EGFRKDRAURKABRAF | |
| SCHEMBL4418947 | 0.83 | EGFR (0.60) | EGFRKDRAURKABRAF | |
| SCHEMBL6775046 | 0.81 | KDR (0.44) | EGFRKDRBRAF | |
| SCHEMBL5498170 | 0.81 | EGFR (0.64) | EGFRKDR | |
| SCHEMBL4431432 | 0.80 | ADRA2A (0.47) | AURKABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | EGFR 1578/4885KDR 39/4885AURKA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.